(NYSEMKT: AEON) Aeon Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.28%.
Aeon Biopharma's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast AEON's revenue for 2026 to be $0, with the lowest AEON revenue forecast at $0, and the highest AEON revenue forecast at $0. On average, 3 Wall Street analysts forecast AEON's revenue for 2027 to be $28,495,142, with the lowest AEON revenue forecast at $27,382,328, and the highest AEON revenue forecast at $29,335,672.
In 2028, AEON is forecast to generate $434,707,774 in revenue, with the lowest revenue forecast at $417,660,410 and the highest revenue forecast at $447,493,297.